<DOC>
	<DOCNO>NCT00010868</DOCNO>
	<brief_summary>This 12 month study omega-3 fatty acid bipolar disorder . This study 12-month , parallel group , double-blind comparison prophylactic efficacy omega-3 fatty acid vs. placebo 120 bipolar I patient . All subject enter primary prophylactic study euthymic subsyndromal mood symptom least 4 week . In addition , concomitant medication ( lithium , divalproex , medication permit ) also stable accept therapeutic level least 4 week . An 8-week lead-in phase available subject meet current symptom concomitant medication inclusion criterion ( however , subject must meet inclusion/exclusion criterion ) : 1 . 4 week euthymic subsyndromal mood . 2 . Subjects already receive lithium divalproex . 3 . Subjects receive psychotropic medication .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Meet DSMIV criterion bipolar disorder , type I . Have episode mania , hypomania , mixed mania , major depression within precede 12 month , define SCID criterion . Able give inform consent . Patients significant medical comorbidity , active hepatic renal disease , type coagulopathy , lipidoses , dementia , history significant head injury , active cancer cancer treatment , medical problem may interfere absorption metabolism omega3 fatty acid . In addition , medical disorder symptom ( e.g . aphasia , encephalopathy , etc . ) would make difficult determine clinical response study drug . Patients significant psychiatric comorbidity , another currently active Axis 1 2 disorder require treatment . Patients , active mental disorder may psychiatric symptom would make difficult assess mood response study drug . For example , patient significant anxiety panic symptom require medication would exclude , whereas patient past currently mild anxiety symptom require active treatment would eligible . Patients receive Coumadin , drug strong effect coagulation exclude due theoretical increase risk bleed omega3 fatty acid therapy . Low dose intermittent NSAIDs permit . Patients receive drug affect lipid metabolism , HMG CoA inhibitor , highdose niacin , gemfibrozil , others . Pregnant patient due unknown effect high dose omega3 fatty acid fetus . Patients , investigator 's judgment pose current serious suicidal homicidal risk , patient likely able comply study protocol . Bipolar patient receive clozapine . These patient exclude due likelihood extreme treatment resistance clozapinetreated bipolar disorder . It may unwise discontinue patient 's clozapine , since recurrence may occur . Also , base uncontrolled data , clozapine may uniquely effective mood stabilizer , would add potential confound study . Patients meet DSMIV criterion substance abuse within 1 month trial substance dependence within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>eicosapentaenoic acid</keyword>
	<keyword>docosahexaenoic acid</keyword>
</DOC>